Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

AS-OCT Guided Treatment of Diffuse CSCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03515954
Recruitment Status : Completed
First Posted : May 4, 2018
Last Update Posted : January 1, 2019
Sponsor:
Information provided by (Responsible Party):
Tarek Roshdy mohamed Mahgoub ELhamaky, Benha University

Brief Summary:
A prospective study was performed on 8 eyes of 8 patients who underwent amniotic membrane graft after diffuse conjunctival squamous cell neoplasia excision followed by topical mitomycin C 0.04% eye drop between March 2014 and January 2018.

Condition or disease Intervention/treatment
Conjunctival Neoplasms Procedure: Treatment of diffuse ocular surface squamous neoplasia

Detailed Description:
Surgical excision of the conjunctival tumour . A superficial corneal scraping was performed for corneal lesion then double freeze-thaw cryotherapy was applied to limbal edge and conjunctival margins.The amniotic membrane graft was secure and attached to the sclera and conjunctiva using fibrin glue.Topical mitomycin C 0.04%eye drop was prescribed 4 times daily per treatment cycle (1 cycle=1 week on 1 week off).

Layout table for study information
Study Type : Observational
Actual Enrollment : 15 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Anterior Segment Optical Coherence Tomography (AS-OCT) Guided Treatment of Diffuse Conjunctival Squamous Cell Carcinoma (CSCC) With Excision, Amniotic Membrane Graft Using Fibrin Glue and Topical Mitomycin C (MMC)
Actual Study Start Date : March 2014
Actual Primary Completion Date : January 2018
Actual Study Completion Date : October 2018

Intervention Details:
  • Procedure: Treatment of diffuse ocular surface squamous neoplasia
    Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.


Primary Outcome Measures :
  1. The recurrence rate of lesion [ Time Frame: 2 years ]
    Any recurrence which is detected clinically or/and by AS-OCT



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
This study included 8 eyes of 8 patients. The mean age of all patients was 51.9 ± 9.9 years. There were 7 males (87.5%) and 1 female (12.5%).
Criteria

Inclusion Criteria:

  • diffuse Ocular Surface Squamous Neoplasia

Exclusion Criteria:

  • localized OSSN (less than five clock hours in limbal extent)

Layout table for additonal information
Responsible Party: Tarek Roshdy mohamed Mahgoub ELhamaky, lecturer of ophthalmology, Benha University
ClinicalTrials.gov Identifier: NCT03515954     History of Changes
Other Study ID Numbers: benha19992
First Posted: May 4, 2018    Key Record Dates
Last Update Posted: January 1, 2019
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tarek Roshdy mohamed Mahgoub ELhamaky, Benha University:
conjunctiva
squamous neoplasia
amniotic
Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctival Neoplasms
Eye Neoplasms
Neoplasms by Site
Neoplasms
Conjunctival Diseases
Eye Diseases